



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006, 235704 Fax : +91-8532-235876

E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

CIN No. L85110KA1987PLC008739

SML/826/2015-16

Dated 7<sup>th</sup> November, 2015

To,  
The Corporate Relationship Department,  
BSE Limited, 1<sup>st</sup> Floor,  
P.J Towers, Dalal Street,  
Mumbai - 400 001.

Dear Sir/Madam,

**Sub: Submission of Revised Un-audited Financial Results for the quarter and half-year ended  
30<sup>th</sup> September, 2015.**

**Ref: SCRIP CODE & ID: 530549.**

\*\*\*\*\*

Please find attached herewith the revised Un-audited Financial Results for the quarter and half-year ended 30<sup>th</sup> September, 2015, as there was some typographical errors while entering details in Part II of UFR i.e shareholding details. There is no change in Part I.

Please ignore the previous attachment and kindly take on record the annexed attachment.

Thanking you,

Yours faithfully,  
For SHILPA MEDICARE LIMITED

  
RAMAKANT INNANI  
COMPLIANCE OFFICER



Encl:a.a



## SHILPA MEDICARE LIMITED

Regd. Office: # 10/80, First Floor, Rajendra Gunj, Raichur-584102 (Karnataka)

UNAUDITED FINANCIAL RESULTS FOR 2ND QUARTER ENDED 30TH SEPTEMBER-2015

(Rs in Lacs)

**PART-I**

	Particulars	Quarter Ended- Unaudited						Half Year Ended - Unaudited				Year Ended - Audited	
		Standalone			Consolidated			Standalone		Consolidated		Standalone	Consolidated
		30.09.15	30.06.15	30.09.14	30.09.15	30.06.15	30.09.14	30.09.15	30.09.14	30.09.15	30.09.14	31.03.15	31.03.15
1	<b>Income from operations</b>												
	(a) Net sales/income from operations (Net of Excise Duty)	16342.18	14385.67	14335.49	17327.36	14850.48	15366.24	30727.84	27008.09	32177.84	29256.43	56540.21	61379.91
	<b>Total income from operations (net)</b>	<b>16342.18</b>	<b>14385.67</b>	<b>14335.49</b>	<b>17327.36</b>	<b>14850.48</b>	<b>15366.24</b>	<b>30727.84</b>	<b>27008.09</b>	<b>32177.84</b>	<b>29256.43</b>	<b>56540.21</b>	<b>61379.91</b>
2	<b>Expenses</b>												
	(a) Cost of materials consumed	8069.46	10209.79	8173.11	8285.38	10324.65	8437.40	18279.25	14403.84	18610.03	15032.43	30786.61	31902.43
	(b) Purchases of stock-in-trade	42.38	28.74	194.66	42.38	28.74	194.66	71.12	295.72	71.12	295.72	606.83	606.83
	(c) Changes in inventories of finished goods, WIP,	516.91	-2290.81	4.18	425.93	-2350.48	135.68	-1773.89	962.30	-1924.55	981.47	(311.15)	(39.38)
	(d) Employee benefits expense	1604.52	1506.49	1257.42	2184.88	2068.88	1942.90	3111.00	2433.98	4253.76	3798.31	5648.85	8230.11
	(e) Depreciation and amortisation expense	518.58	484.45	449.70	647.64	532.53	510.99	1003.04	944.31	1180.17	1063.62	1908.50	2141.17
	(f) Other expenses	2095.64	1660.78	1557.27	2643.15	1955.39	1886.29	3756.42	2691.85	4598.54	3428.03	6156.29	7816.38
	<b>Total Expense</b>	<b>12847.48</b>	<b>11599.44</b>	<b>11636.34</b>	<b>14229.35</b>	<b>12559.71</b>	<b>13107.92</b>	<b>24446.94</b>	<b>21732.00</b>	<b>26789.05</b>	<b>24599.58</b>	<b>44795.93</b>	<b>50657.54</b>
3	<b>Profit/(Loss) from Operations before Other Income, Finance Costs &amp; exceptional items (1-2)</b>	<b>3494.70</b>	<b>2786.23</b>	<b>2699.15</b>	<b>3098.01</b>	<b>2290.77</b>	<b>2258.32</b>	<b>6280.91</b>	<b>5276.09</b>	<b>5388.78</b>	<b>4656.85</b>	<b>11744.28</b>	<b>10722.37</b>
4	<b>Other Income</b>	219.39	75.72	209.35	178.58	18.49	217.15	295.11	355.34	197.07	318.45	545.34	479.89
5	<b>Profit/(Loss) from Ordinary activities before finance cost &amp; exceptional items (3+/-4)</b>	<b>3714.10</b>	<b>2861.95</b>	<b>2908.50</b>	<b>3276.59</b>	<b>2309.26</b>	<b>2475.47</b>	<b>6576.02</b>	<b>5631.43</b>	<b>5585.85</b>	<b>4975.30</b>	<b>12289.62</b>	<b>11202.26</b>
6	<b>Finance costs</b>	93.10	80.75	104.23	150.01	82.02	105.46	173.84	200.00	232.02	206.31	387.98	405.02
7	<b>Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5 +/- 6)</b>	<b>3621.00</b>	<b>2781.20</b>	<b>2804.27</b>	<b>3126.58</b>	<b>2227.24</b>	<b>2370.01</b>	<b>6402.18</b>	<b>5431.43</b>	<b>5353.83</b>	<b>4768.99</b>	<b>11901.64</b>	<b>10797.24</b>
8	<b>Exceptional items*</b>	241.96	0.00	0.00	241.96	0.00	-	241.96	0.00	241.96	0.00	0.00	0.00
9	<b>Profit/(Loss) from Ordinary Activities before tax (7 +/- 8)</b>	<b>3379.04</b>	<b>2781.20</b>	<b>2804.27</b>	<b>2884.63</b>	<b>2227.24</b>	<b>2370.01</b>	<b>6160.22</b>	<b>5431.43</b>	<b>5111.87</b>	<b>4768.99</b>	<b>11901.64</b>	<b>10797.24</b>
10	<b>Tax expense</b>	966.23	653.20	595.98	882.07	651.03	649.11	1619.43	1319.21	1533.10	1369.53	3483.53	3521.58
11	<b>Net Profit/(Loss) from ordinary activities after tax (9)</b>	<b>2412.81</b>	<b>2128.00</b>	<b>2208.29</b>	<b>2002.56</b>	<b>1576.21</b>	<b>1720.90</b>	<b>4540.79</b>	<b>4112.22</b>	<b>3578.77</b>	<b>3399.46</b>	<b>8418.11</b>	<b>7275.66</b>
12	<b>Extraordinary Items Income / (Expenses)</b>	0.00	0.00	0.00	0.10	0.00	4.96	0.00	0.00	0.10	4.96	0.00	(4.83)
13	<b>Net Profit/(Loss) for the period (11+12)</b>	<b>2412.81</b>	<b>2128.00</b>	<b>2208.29</b>	<b>2002.66</b>	<b>1576.21</b>	<b>1715.94</b>	<b>4540.79</b>	<b>4112.22</b>	<b>3578.87</b>	<b>3394.50</b>	<b>8418.11</b>	<b>7270.82</b>
14	<b>Share of Profit / (Loss) of associates</b>	0.00	-	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	-	-
15	<b>Add:(Gain)/ loss pertaining to Minority Interest</b>	0.00	-	0.00	219.79	29.71	13.57	0.00	0.00	249.50	42.27	-	106.65
16	<b>Net Profit / (loss) after taxes, minority interest and share of profit/(loss) of associates (13+/-14+/-15)</b>	<b>2412.81</b>	<b>2128.00</b>	<b>2208.29</b>	<b>2222.45</b>	<b>1605.92</b>	<b>1729.51</b>	<b>4540.79</b>	<b>4112.22</b>	<b>3828.37</b>	<b>3436.77</b>	<b>8418.11</b>	<b>7377.47</b>
17	<b>Paid-up equity share capital (Face value of Rs 2/-)</b>	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02	771.02
18	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	-	-	-	-	-	-	-	-	55538.56	53923.10
19.i	<b>Earnings Per Share (EPS) (before extraordinary items)</b> (of Rs.2/- each) (not annualized):												
	a) Basic	6.26	5.52	5.73	5.76	4.17	4.50	11.78	10.67	9.93	8.93	21.94	19.23
	b) Diluted	6.26	5.52	5.73	5.76	4.17	4.50	11.78	10.67	9.93	8.93	21.94	19.23
19.ii	<b>Earnings Per Share (EPS) (after extraordinary items)</b> (of Rs.2/- each) (not annualized):												
	a) Basic	6.26	5.52	5.73	4.17	4.17	4.54	11.78	10.67	9.93	8.92	21.94	19.22
	b) Diluted	6.26	5.52	5.73	4.17	4.17	4.54	11.78	10.67	9.93	8.92	21.94	19.22



## PART-II

A. PARTICULARS OF SHARE HOLDING													
1	Public Shareholding												
	- Number of Shares	18099606	18099606	18097294	18099606	18099606	18097294	18099606	18097294	18099606	18097294	18099606	18099606
	- Percentage of shareholding	46.95	46.95	46.94	46.95	46.95	46.94	46.95	46.94	46.95	46.94	46.95	46.95
2	Promoters & Promoters group Shareholding												
	a) Pledged / Encumbered												
	- Number of shares	0	0	0	0	0	0	0	0	0	0	0	0
	- Percentage of shares (as a % of the total share of promoter and promoter group)	-	-	-	-	-	-	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share of the company)	-	-	-	-	-	-	-	-	-	-	-	-
	b) Non encumbered												
	- Number of shares	20451346	20451346	20453658	20451346	20451346	20453658	20451346	20453658	20451346	20453658	20451346	20451346
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share of the company)	53.05	53.05	53.06	53.05	53.05	53.06	53.05	53.06	53.05	53.06	53.05	53.05
B. PARTICULARS OF INVESTOR COMPLAINTS													
Three Months ended 30th Sept,2015													
Particulars													
Pending at the beginning of the quarter								Nil					
Received during the quarter								39					
Disposed off during the quarter								39					
Remaining unresolved at the end of the quarter								Nil					


## Notes:

- Exceptional items comprise the impact of reduction of Shilpa Medicare Ltd's shareholding in its US Subsidiary Makindus Inc from 70% to 55.78%
- The Unaudited Financial Results have been reviewed by the Audit Committee and approved at the board meeting and have undergone limited review by the Statutory Auditors.
- Figures of the previous year/quarter have been regrouped/rearranged wherever necessary.
- Tax Expenses includes Current and Deferred Tax.
- As per As-17 reporting segment is only one i.e. Bulk Drug & API. Therefore segment reporting is not applicable.
- Q2 - Consolidated Results include sales figure of Rs.25.88 Lakhs (Nil) and net loss of Rs.76.83 (Profit - Rs.19.49) Lakhs respectively of Raichem Medicare Pvt Ltd (subsidiary Co) which has just started its operations w.e.f 25.08.2015
- H1 - Consolidated Results include sales figure of Rs.25.88 Lakhs (Nil) and net loss of Rs.75.31 (Profit - Rs.20.07) Lakhs respectively of Raichem Medicare Pvt Ltd (subsidiary Co) which has just started its operations w.e.f 25.08.2015
- Q2 - Consolidated Results include a figure of Nil (Nil) sales and net loss of Rs.188.66 (Loss-114.65) Lakhs in respect of maia, Makindus and INM Technologies Pvt Ltd taken together which are subsidiaries/ JV cos of shilpa medicare Ltd and which are in the investment phase of their R&D activities and are yet to start generating operational revenues.
- H1- Consolidated Results include a figure of Nil (Nil) sales and net loss of Rs.327.39 (Loss-257.28) Lakhs in respect of Maia, Makindus and INM Technologies Pvt Ltd taken together which are subsidiaries/associate JV cos of shilpa medicare ltd and which are in the investment phase of their R&D activities and are yet to start generating operational revenues.

\* Figures in brackets represents amount for corresponding previous period.

Place:Hyderabad  
Date:07/11/2015

By the order of the Board of Directors  
for SHILPA MEDICARE LIMITED

  
Chairman





**STANDALONE/CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER-15**  
(Rs. In Lacs)

Particulars	Standalone		Consolidated	
	30.09.2015	30.09.2014	30.09.2015	30.09.2014
	Unaudited	Unaudited	Unaudited	Unaudited
<b>A. EQUITY AND LIABILITIES</b>				
<b>1. Shareholder's funds</b>				
(a) Share Capital	771.02	771.02	771.02	771.02
(b) Reserves and Surplus	60391.80	52092.53	57822.97	49936.55
<b>Sub.total-Shareholder's funds</b>	<b>61162.82</b>	<b>52863.55</b>	<b>58593.99</b>	<b>50707.57</b>
<b>2. Minority Interest</b>			1395.03	1459.70
<b>3. Non-Current Liabilities</b>				
(a) Long-term borrowings	821.76	2761.93	10917.94	12035.52
(b) Deferred tax liabilities (net)	4201.93	3156.59	3988.71	3077.34
(c) Other Long term liabilities	0.00	0.00	1283.29	996.00
(d) Long-term provisions	380.87	99.89	310.02	173.13
<b>Sub.total-Non-current liabilities</b>	<b>5404.57</b>	<b>6018.41</b>	<b>16499.97</b>	<b>16281.98</b>
<b>4. Current Liabilities</b>				
(a) Short-term borrowings	6571.33	4278.61	7669.97	5061.08
(b) Trade payables	7501.07	4993.55	9059.38	5772.58
(c) Other current liabilities	4674.67	4160.84	6843.03	4527.48
(d) Short-term provisions	538.40	399.56	567.50	468.15
<b>Sub.total-Current liabilities</b>	<b>19285.47</b>	<b>13832.55</b>	<b>24139.87</b>	<b>15829.29</b>
<b>TOTAL-EQUITY AND LIABILITIES</b>	<b>85852.86</b>	<b>72714.51</b>	<b>100628.86</b>	<b>84278.54</b>
<b>B. ASSETS</b>				
<b>1. Non-current Assets</b>				
(a) Goodwill on Consolidation			1906.61	1487.81
(b) Fixed assets (Net Block)				
(i) Tangible /Intangible assets	31614.80	28016.83	49824.18	30053.78
(ii) Capital work-in-progress	9831.91	5621.43	10710.64	15265.89
	<b>41446.71</b>	<b>33638.26</b>	<b>62441.43</b>	<b>46807.48</b>
(c) Non current investments	8245.51	7328.98	20.74	19.48
(d) Long-term loans and advances	3160.54	3825.32	4163.90	4759.39
(e) Other non-current assets	0.00	0.00	14.31	18.26
<b>Sub.total-Non-current assets</b>	<b>52852.75</b>	<b>44792.56</b>	<b>66640.37</b>	<b>51604.60</b>
<b>2. Current Assets</b>				
(a) Current investments	6286.75	7068.55	6334.07	7068.55
(b) Inventories	14602.06	9121.42	16305.72	10512.00
(c) Trade receivables	6055.19	5885.45	6657.99	6539.85
(d) Cash and cash equivalents	265.67	832.39	994.71	5426.07
(e) Short-term loans and advances	4802.54	4391.40	2840.22	2464.49
(f) Other current assets	987.89	622.74	855.78	662.96
<b>Sub.total-Current assets</b>	<b>33000.11</b>	<b>27921.95</b>	<b>33988.49</b>	<b>32673.93</b>
<b>TOTAL-ASSETS</b>	<b>85852.86</b>	<b>72714.51</b>	<b>100628.86</b>	<b>84278.54</b>

Place:Hyderabad

Date:07/11/2015

By the order of the Board of Directors

for SHILPA MEDICARE LIMITED

Chairman



# Bohara Bhandari Bung And Associates LLP

Chartered Accountants

#12-10-89/1, 2<sup>nd</sup> Floor, Anagha Complex,

Above Canara Bank, Saath Kacheri Road,

Raichur - 584101

Tel No. +91(8532) 232403, 231902

## Auditor's Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of

Shilpa Medicare Limited

We have reviewed the quarterly unaudited financial results of Shilpa Medicare Limited ('the Company') for the quarter ended September 30, 2015 being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results have been prepared by the Company pursuant to clause 41 of the Listing Agreement and are the responsibility of the Company's management and have been approved by the Board of Directors. Our responsibility is to issue a report on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

### Matter of Emphasis

Without qualifying our report on the audited financial results, we state that the Company has filed a lawsuit for recovering its amount of Rs.339.29 Lakhs which is paid as capital advance to its vendor for supply of Capital Asset, along with punitive damages. The Preliminary hearings of the case are in progress. The ultimate outcome of the matter cannot presently be determined, and hence no provision for the outstanding balance receivable from the party has been made in the financial statements. Our Report is not qualified on this matter.

Based on our review conducted and subject to Matter of emphasis mentioned at Point No.03 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in all material respects in accordance with applicable accounting standards read with the General Circular 15/2013 dated September 13,2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bohara Bhandari Bung & Associates LLP

Chartered Accountants

(Firm Regn No. 008127S/S200013)

CA.Pankajkumar Bohara

Partner

M.No: 215471

Place / Camp: Hyderabad

Date: 07.11.2015



# Bohara Bhandari Bung And Associates LLP

Chartered Accountants

#12-10-89/1, 2<sup>nd</sup> Floor, Anagha Complex,

Above Canara Bank, Saath Kacheri Road,

Raichur - 584101

Tel No. +91(8532) 232403, 231902

## Auditor's Report on Unaudited Quarterly Consolidated Financial Results of the Company Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of


Shilpa Medicare Limited

1. We have reviewed the Unaudited quarterly consolidated financial results of **Shilpa Medicare Limited** ("the Company"), its Subsidiaries and Joint Ventures ("Collectively known as Group") for the quarter ended September 30th, 2015 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Company which have been traced from disclosures made by the management but have neither been reviewed nor been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue an report on these statements based on our review
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. **Matter of Emphasis**  
Without qualifying our report on the audited financial results, we state that the Company has filed a lawsuit for recovering its amount of Rs.339.29 Lakhs which is paid as capital advance to its vendor for supply of Capital Asset, along with punitive damages. The Preliminary hearings of the case are in progress. The ultimate outcome of the matter cannot presently be determined, and hence no provision for the outstanding balance receivable from the party has been made in the financial statements. Our Report is not qualified on this matter.
4. We did not review the financial results of 05 subsidiaries and 01 Joint Venture (JV) considered in the preparation of the consolidated unaudited results and whose total revenues constitutes Rs.1,021.30 Lakhs and net loss of Rs.399.72 Lakhs to the extent of the Company share for the quarter ended September 30, 2015, respectively, These unaudited financial statements and other financial information of the above subsidiaries and JV, which have neither been audited nor reviewed, have been prepared by the management and provided to us by the Management, and our opinion is based solely on these unaudited financial statements.
5. Based on our review conducted and subject to Matter of emphasis mentioned at Point No.03 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in all material respects in accordance with applicable accounting standards read with the General Circular 15/2013 dated September 13,2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bohara Bhandari Bung & Associates LLP

Chartered Accountants

(Firm Regn No. 008127S/S200013)



CA. Pankaj Kumar Bohara

Partner

M.No. 215471

Place / Camp: Hyderabad

Date: 07.11.2015

